Greenwich LifeSciences announced its board has extended the lock-up of shares owned by directors, officers, and pre-IPO investors to January 31, 2027, roughly 76 months from its IPO. During this period, those insiders cannot sell their common stock unless the board modifies the restriction. After the lock-up expires, daily and periodic sales will be governed by a leak-out plan, though the board may end the lock-up early for strategic or financial transactions. CEO Snehal Patel noted the company expects increased interest in partnership and financing discussions following progress in its Phase III FLAMINGO-01 trial for the GLSI-100 immunotherapy.
Greenwich Lifesciences IncLock-up extension reduces potential share supply, supporting stock price; CEO notes increased partnership/financing interest.
